Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZENITH NEGOTIATING THREE-YEAR SUPPLY DEAL WITH SQUIBB

Executive Summary

ZENITH NEGOTIATING THREE-YEAR SUPPLY DEAL WITH SQUIBB for "selected" generic products to be sold under the SquibbMark label, Zenith announced in a June 18 press release. The disclosure was made at the Zenith annual shareholders meeting in Park Ridge, New Jersey, and repeated in the follow up press release. "The agreement is expected to include certain Zenith products that are currently on the market and others for which new drug applications are pending approval from the U.S. FDA," the release states. "The product to be manufactured for the SquibbMark label will be produced by Zenith in conformity with quality assurance and quality control procedures of Squibb, as is the case for any supplier." Zenith's most recent ANDA approvals include three oral cephalosporin products: cephadrine -- Squibb's Velocef and SmithKline's Anspor; cefadroxil -- Bristol-Myers Duricef and Ultracef; and cephalexin -- Lilly's Ceclor.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012083

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel